Loading…
Transparent Drug Pricing Act of 2017
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
44pct
2d open
vs 7,393 other HR bills in the 115th — cohort avg 50d
Transparent Drug Pricing Act of 2017 This bill requires drug manufacturers to report specified financial and sales information, including drug pricing, tax credit, and patent information; violations are subject to civil penalties.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (5)
2018 · fourth_quarter · Health Issues
Referred to the Subcommittee on Health.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
S. 92: Safe and Affordable Drugs from Canada Act S. 469: Affordable and Safe Prescription Drug Importation Act S. 1131/ H.R. 2439: FAIR Drug Pricing Act S. 1348: SPIKE Act of 2017 S. 1369/ H.R. 2974: Stop Price Gouging Act S. 1803/H.R. 4825, the Marijuana Effective Drug Studies (MEDS) Act S. 2076/H.R. 4256: BOLD Infrastructure for Alzheimer's Act S. 2406: Advancing Cutting Edge (ACE) Research Act S. 2478: End Taxpayer Subsidies for Drug Ads Act S. 2680: Opioid Crisis Response Act S. 2891: Fighting the Opioid Epidemic with Sunshine Act S. 3369/ HR 6689: Ensuring Lasting Smiles Act S. 3411/H.R. 6689: Affordable Medications Act S. 3657/ H.R. 6615: Traumatic Brain Injury Program Reauthorization Act S. 3686/ H.R. 3580: Protecting Student Athletes from Concussions Act H.R. 6: SUPPORT for Patients and Communities Act: Sections 6062 and 6111; Subtitle E H.R. 1776: Improving Access to Affordable Prescription Drugs Act H.R. 2077: Restoring the Patient's Voice Act H.R. 3391, Medical Marijuana Research Act of 2017 H.R. 4116: Transparent Drug Pricing Act H.R. 5634: Medical Cannabis Research Act H.R. 6340: Capping Prescription Costs Act Disclosure of drug prices in prescription drug direct-to-consumer advertising; Sustained fetal tissue research; Orphan Drug Act Reform; Interoperability, including for Qualified Clinical Data Registries; NIH funding including the BRAIN Initiative; Congressionally-Directed Medical Research Program funding; concussion related issues; loan repayment for pediatric specialists.
Client expense: $140,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · third_quarter · Health Issues
S. 92: Safe and Affordable Drugs from Canada Act S. 469: Affordable and Safe Prescription Drug Importation Act S. 1131/ H.R. 2439: FAIR Drug Pricing Act S. 1348: SPIKE Act of 2017 S. 1369/ H.R. 2974: Stop Price Gouging Act S. 2260 / H.R. 4733: Opioids and STOP Pain Initiative Act S. 2406: Advancing Cutting Edge (ACE) Research Act S. 2478: End Taxpayer Subsidies for Drug Ads Act S. 2680: Opioid Crisis Response Act S. 2891: Fighting the Opioid Epidemic with Sunshine Act S. 3369/ H.R. 6689: Ensuring Lasting Smiles Act S. 3411: Affordable Medications Act H.R. 6: SUPPORT for Patients and Communities Act: Sections 6062 and 6111; Subtitle E H.R. 1776: Improving Access to Affordable Prescription Drugs Act H.R. 2077: Restoring the Patient's Voice Act H.R. 4116: Transparent Drug Pricing Act H.R. 5634: Medical Cannabis Research Act H.R. 6340: Capping Prescription Costs Act Interoperability, including for Qualified Clinical Data Registries; Appropriations for the CDC National Neurological Conditions Surveillance System; Maintenance/expansion of Graduate Medical Education (GME); NIH funding including the BRAIN Initiative; Congressionally-Directed Medical Research Program funding; concussion related issues.
Client expense: $250,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · second_quarter · Health Issues
S. 92: Safe and Affordable Drugs from Canada Act S. 201 / H.R. 5247: Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017 S. 469: Affordable and Safe Prescription Drug Importation Act S. 1131/ H.R. 2439: FAIR Drug Pricing Act S. 2260 / H.R. 4733: Opioids and STOP Pain Initiative Act H.R. 1776: Improving Access to Affordable Prescription Drugs Act H.R. 1876: Good Samaritan Health Professionals Act of 2017 H.R. 2077: the Restoring the Patient's Voice Act of 2017 H.R. 4116: Transparent Drug Pricing Act of 2017 S. 2387 / H.R. 4957: Concentrating on High-Value Alzheimers Needs to Get to an End (CHANGE) Act S. 2406: Advancing Cutting Edge (ACE) Research Act S. 2478: End Taxpayer Subsidies for Drug Ads Act S. 2680: Opioid Crisis Response Act of 2018 S. 2891: Fighting the Opioid Epidemic with Sunshine Act H.R. 5634: Medical Cannabis Research Act Maintenance/expansion of Graduate Medical Education (GME); encouraging drug price transparency; NIH funding including the BRAIN Initiative; Congressionally-Directed Medical Research Program funding; concussion related issues.
Client expense: $220,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · first_quarter · Health Issues
S. 92: Safe and Affordable Drugs from Canada Act S. 201 / H.R. 5247: Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017 S. 469: Affordable and Safe Prescription Drug Importation Act S. 1131/ H.R. 2439: FAIR Drug Pricing Act S. 1827/ H.R. 3921 HEALTHY KIDS Act S. 2076 /H.R. 4256: Building Our Largest Dementia (BOLD) Infrastructure for Alzheimers Act S. 2260 / H.R. 4733: Opioids and STOP Pain Initiative Act H.R. 1625 Vehicle for Consolidated Appropriations Act 2018 H.R. 1776: Improving Access to Affordable Prescription Drugs Act H.R. 1876: Good Samaritan Health Professionals Act of 2017 H.R. 1892: Continuing Resolution through March 23, 2018 H.R. 2077: the Restoring the Patient's Voice Act of 2017 H.R. 4116: Transparent Drug Pricing Act of 2017 H.R. 4841: Legislation to improve electronic prior authorization use in Medicare Advantage Maintenance/expansion of Graduate Medical Education (GME); encouraging drug price transparency; NIH funding including the BRAIN Initiative; Congressionally-Directed Medical Research Program funding; concussion related issues.
Client expense: $620,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · fourth_quarter · Health Issues
S. 92: Safe and Affordable Drugs from Canada Act S. 469: Affordable and Safe Prescription Drug Importation Act S. 1131/ H.R. 2439: FAIR Drug Pricing Act S. 1348: SPIKE Act of 2017 S. 1369/ H.R. 2974: Stop Price Gouging Act S. 1803/H.R. 4825, the Marijuana Effective Drug Studies (MEDS) Act S. 2076/H.R. 4256: BOLD Infrastructure for Alzheimer's Act S. 2406: Advancing Cutting Edge (ACE) Research Act S. 2478: End Taxpayer Subsidies for Drug Ads Act S. 2680: Opioid Crisis Response Act S. 2891: Fighting the Opioid Epidemic with Sunshine Act S. 3369/ HR 6689: Ensuring Lasting Smiles Act S. 3411/H.R. 6689: Affordable Medications Act S. 3657/ H.R. 6615: Traumatic Brain Injury Program Reauthorization Act S. 3686/ H.R. 3580: Protecting Student Athletes from Concussions Act H.R. 6: SUPPORT for Patients and Communities Act: Sections 6062 and 6111; Subtitle E H.R. 1776: Improving Access to Affordable Prescription Drugs Act H.R. 2077: Restoring the Patient's Voice Act H.R. 3391, Medical Marijuana Research Act of 2017 H.R. 4116: Transparent Drug Pricing Act H.R. 5634: Medical Cannabis Research Act H.R. 6340: Capping Prescription Costs Act Disclosure of drug prices in prescription drug direct-to-consumer advertising; Sustained fetal tissue research; Orphan Drug Act Reform; Interoperability, including for Qualified Clinical Data Registries; NIH funding including the BRAIN Initiative; Congressionally-Directed Medical Research Program funding; concussion related issues; loan repayment for pediatric specialists.
Client expense: Not reported · Firm income: $140,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · fourth_quarter · Pharmacy
HR 6505-Medicare Negotiation and competitive licensing act, S 1369/HR 2974-Stop price gouging Act, HR 6577-PRICED Act, S 124-Preserve access to affordable generics act, HR 4117-competitive drugs act, S 974/HR 2212-CREATES act, drug pricing, HR 4116-Transparent drug pricing act, HR 1776-Improving access to affordable prescription drugs act, S 3680-Low Drug Prices act, HR 676-Expanded and Improved Medicare for all act, S 3775-Affordable drug manufacturing act,
Client expense: $70,000 · Firm income: Not reported
Government targets: Commodity Futures Trading Commission (CFTC), Federal Deposit Insurance Corporation (FDIC), Federal Reserve System, HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), U.S. Trade Representative (USTR)
2018 · fourth_quarter · Advertising
H.R.1776/ S.771, Improving Access To Affordable Prescription Drugs Act H.R. 2439/ S.1131, Fair Accountability and Innovative Research Drug Pricing Act S.1348, Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act H.R.4385, Responsibility in Drug Advertising Act H.R.4116, Transparent Drug Pricing Act S.2157, Drug-Price Transparency in Communications Act S.2478, End Taxpayer Subsidies for Drug Ads Act FTC Reauthorization Act of 2018 (Not introduced)
Client expense: Not reported · Firm income: $90,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · fourth_quarter · Medicare/Medicaid
General Medicare Protection, Prevention of Fraud, Waste, and Abuse: H.R. 2460 and H.R. 4841 and H.R. 4704, Prescription Drug Re-Importation: S. 92 and S. 469 and H.R. 1245, Negotiation of Prescription Drug Prices: H.R. 242 and S. 41, General Prescription Drug Affordability: S. 124 and S. 771 and H.R. 1776 and H.R. 4138 and H.R. 4116 and H.R. 4117 and S. 2011 and S. 974 and H.R. 2212 and S. 2553, Medicare Enrollment Simplification: H.R. 2575 and S. 1909, Expanding Medicare Coverage: H.R. 5083 and H.R. 4957 and S. 2387 and H.R. 807 and H.R. 3098 and H.R. 4701 and H.R. 508 and H.R. 2276 and S. 2575 and H.R. 5083.
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · third_quarter · Health Issues
S. 92: Safe and Affordable Drugs from Canada Act S. 469: Affordable and Safe Prescription Drug Importation Act S. 1131/ H.R. 2439: FAIR Drug Pricing Act S. 1348: SPIKE Act of 2017 S. 1369/ H.R. 2974: Stop Price Gouging Act S. 2260 / H.R. 4733: Opioids and STOP Pain Initiative Act S. 2406: Advancing Cutting Edge (ACE) Research Act S. 2478: End Taxpayer Subsidies for Drug Ads Act S. 2680: Opioid Crisis Response Act S. 2891: Fighting the Opioid Epidemic with Sunshine Act S. 3369/ H.R. 6689: Ensuring Lasting Smiles Act S. 3411: Affordable Medications Act H.R. 6: SUPPORT for Patients and Communities Act: Sections 6062 and 6111; Subtitle E H.R. 1776: Improving Access to Affordable Prescription Drugs Act H.R. 2077: Restoring the Patient's Voice Act H.R. 4116: Transparent Drug Pricing Act H.R. 5634: Medical Cannabis Research Act H.R. 6340: Capping Prescription Costs Act Interoperability, including for Qualified Clinical Data Registries; Appropriations for the CDC National Neurological Conditions Surveillance System; Maintenance/expansion of Graduate Medical Education (GME); NIH funding including the BRAIN Initiative; Congressionally-Directed Medical Research Program funding; concussion related issues.
Client expense: Not reported · Firm income: $250,000
2018 · third_quarter · Medicare/Medicaid
General Medicare Protection, Prevention of Fraud, Waste, and Abuse: H.R. 2460 and H.R. 4841 and H.R. 4704, Prescription Drug Re-Importation: S. 92 and S. 469 and H.R. 1245, Negotiation of Prescription Drug Prices: H.R. 242 and S. 41, General Prescription Drug Affordability: S. 124 and S. 771 and H.R. 1776 and H.R. 4138 and H.R. 4116 and H.R. 4117 and S. 2011 and S. 974 and H.R. 2212 and S. 2553, Medicare Enrollment Simplification: H.R. 2575 and S. 1909, Expanding Medicare Coverage: H.R. 5083 and H.R. 4957 and S. 2387 and H.R. 807 and H.R. 3098 and H.R. 4701 and H.R. 508 and H.R. 2276 and S. 2575 and H.R. 5083.
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · third_quarter · Advertising
H.R.1776/ S.771, Improving Access To Affordable Prescription Drugs Act H.R. 2439/ S.1131, Fair Accountability and Innovative Research Drug Pricing Act S.1348, Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act H.R.4385, Responsibility in Drug Advertising Act H.R.4116, Transparent Drug Pricing Act S.2157, Drug-Price Transparency in Communications Act S.2478, End Taxpayer Subsidies for Drug Ads Act FTC Reauthorization Act of 2018 (Not introduced)
Client expense: Not reported · Firm income: $90,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · second_quarter · Health Issues
S. 92: Safe and Affordable Drugs from Canada Act S. 201 / H.R. 5247: Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017 S. 469: Affordable and Safe Prescription Drug Importation Act S. 1131/ H.R. 2439: FAIR Drug Pricing Act S. 2260 / H.R. 4733: Opioids and STOP Pain Initiative Act H.R. 1776: Improving Access to Affordable Prescription Drugs Act H.R. 1876: Good Samaritan Health Professionals Act of 2017 H.R. 2077: the Restoring the Patient's Voice Act of 2017 H.R. 4116: Transparent Drug Pricing Act of 2017 S. 2387 / H.R. 4957: Concentrating on High-Value Alzheimers Needs to Get to an End (CHANGE) Act S. 2406: Advancing Cutting Edge (ACE) Research Act S. 2478: End Taxpayer Subsidies for Drug Ads Act S. 2680: Opioid Crisis Response Act of 2018 S. 2891: Fighting the Opioid Epidemic with Sunshine Act H.R. 5634: Medical Cannabis Research Act Maintenance/expansion of Graduate Medical Education (GME); encouraging drug price transparency; NIH funding including the BRAIN Initiative; Congressionally-Directed Medical Research Program funding; concussion related issues.
Client expense: Not reported · Firm income: $220,000
2018 · second_quarter · Pharmacy
S 2011/HR 4138-Medicare Drug Price Negotiation Act, S 974/HR 2212-CREATES Act of 2017, S 124-Preserve Access to Affordable Generics Act, HR 1625-OMNIBUS, opioid addiction data analysis, S 771-Improving access to affordable prescription drugs act, S 252-Medicare Drug Savings act of 2017, S 1369-Stop Price Gouging Act, S 495-Medical innovation and prize fund act, S 1131/HR 2439-FAIR drug pricing act, HR 4117-Competitive Drugs act of 2017, S 771/HR 1776-Improving access to affordable prescription drugs act, S 637-C-THRU Act, S 1347-RxCap Act of 2017, S 1348-SPIKE Act of 2017, HR 5156-Protecting Medicare from Excessive Price Increases Act of 2018, S 2691-Opioid Crisis accountability act of 2018, S 2315-Over the counter drug safety, innovation, and reform act, S 2700/HR 5545-Comprehensive Addiction Resources Emergency (CARE) act, Drug Pricing-Medicare Part D HR 2051-FAST Generics Act of 2017, HR 4116-Transparent Drug Pricing Act, S 2852-Pandemic and All-Hazards Preparedness Act and advancing innovative Act of 2018,
Client expense: $70,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), U.S. Trade Representative (USTR)
2018 · second_quarter · Medicare/Medicaid
General Medicare Protection, Prevention of Fraud, Waste, and Abuse: H.R. 2460 and H.R. 4841 and H.R. 4704, Prescription Drug Re-Importation: S. 92 and S. 469 and H.R. 1245, Negotiation of Prescription Drug Prices: H.R. 242 and S. 41, General Prescription Drug Affordability: S. 124 and S. 771 and H.R. 1776 and H.R. 4138 and H.R. 4116 and H.R. 4117 and S. 2011 and S. 974 and H.R. 2212 and S. 2553, Medicare Enrollment Simplification: H.R. 2575 and S. 1909, Expanding Medicare Coverage: H.R. 5083 and H.R. 4957 and S. 2387 and H.R. 807 and H.R. 3098 and H.R. 4701 and H.R. 508 and H.R. 2276 and S. 2575 and H.R. 5083.
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · second_quarter · Advertising
H.R.1776/ S.771, Improving Access To Affordable Prescription Drugs Act H.R. 2439/ S.1131, Fair Accountability and Innovative Research Drug Pricing Act S.1348, Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act H.R.4385, Responsibility in Drug Advertising Act H.R.4116, Transparent Drug Pricing Act S.2157, Drug-Price Transparency in Communications Act S.2478, End Taxpayer Subsidies for Drug Ads Act FTC Reauthorization Act of 2018 (Not introduced)
Client expense: Not reported · Firm income: $210,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · first_quarter · Health Issues
S. 92: Safe and Affordable Drugs from Canada Act S. 201 / H.R. 5247: Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017 S. 469: Affordable and Safe Prescription Drug Importation Act S. 1131/ H.R. 2439: FAIR Drug Pricing Act S. 1827/ H.R. 3921 HEALTHY KIDS Act S. 2076 /H.R. 4256: Building Our Largest Dementia (BOLD) Infrastructure for Alzheimers Act S. 2260 / H.R. 4733: Opioids and STOP Pain Initiative Act H.R. 1625 Vehicle for Consolidated Appropriations Act 2018 H.R. 1776: Improving Access to Affordable Prescription Drugs Act H.R. 1876: Good Samaritan Health Professionals Act of 2017 H.R. 1892: Continuing Resolution through March 23, 2018 H.R. 2077: the Restoring the Patient's Voice Act of 2017 H.R. 4116: Transparent Drug Pricing Act of 2017 H.R. 4841: Legislation to improve electronic prior authorization use in Medicare Advantage Maintenance/expansion of Graduate Medical Education (GME); encouraging drug price transparency; NIH funding including the BRAIN Initiative; Congressionally-Directed Medical Research Program funding; concussion related issues.
Client expense: Not reported · Firm income: $621,387
2018 · first_quarter · Medicare/Medicaid
General Medicare Protection, Prevention of Fraud, Waste, and Abuse: H.R. 2460 and H.R. 4841 and H.R. 4704, Prescription Drug Re-Importation: S. 92 and S. 469 and H.R. 1245, Negotiation of Prescription Drug Prices: H.R. 242 and S. 41, General Prescription Drug Affordability: S. 124 and S. 771 and H.R. 1776 and H.R. 4138 and H.R. 4116 and H.R. 4117 and S. 2011 and S. 974 and H.R. 2212, Medicare Enrollment Simplification: H.R. 2575 and S. 1909, Expanding Medicare Coverage: H.R. 5083 and H.R. 4957 and S. 2387 and H.R. 807 and H.R. 3098 and H.R. 4701.
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · first_quarter · Advertising
H.R.1776/ S.771, Improving Access To Affordable Prescription Drugs Act H.R. 2439/ S.1131, Fair Accountability and Innovative Research Drug Pricing Act S.1348, Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act H.R.4385, Responsibility in Drug Advertising Act H.R.4116, Transparent Drug Pricing Act S.2157, Drug-Price Transparency in Communications Act S.2478, End Taxpayer Subsidies for Drug Ads Act FTC Reauthorization Act of 2018 (Not introduced)
Client expense: Not reported · Firm income: $240,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · fourth_quarter · Health Issues
S. 92: Safe and Affordable Drugs from Canada Act S. 469: Affordable and Safe Prescription Drug Importation Act S. 771 / H.R. 1776: Improving Access to Affordable Prescription Drugs Act S. 808: Sports Medicine Licensure Clarity Act S. 989/ H.R. 3767: Ensuring Childrens Access to Specialty Care Act S. 1131/ H.R. 2439: FAIR Drug Pricing Act S. 1827/ H.R. 3921 HEALTHY KIDS Act S. 2260 / H.R. 4733: Opioids and STOP Pain Initiative Act H.R. 3197: PUPPERS Act H.R. 3928: Truth in Healthcare Marketing Act of 2017 H.R. 4116: Transparent Drug Pricing Act of 2017 Reauthorization of the Pediatric Subspecialty Loan Repayment Program in Title VII; Maintenance/expansion of Graduate Medical Education (GME); CDC funding; NIH funding including the BRAIN Initiative; DACA renewal; Congressionally-Directed Medical Research Program funding; concussion related issues.
Client expense: $170,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · fourth_quarter · Health Issues
S. 92: Safe and Affordable Drugs from Canada Act S. 469: Affordable and Safe Prescription Drug Importation Act S. 771 / H.R. 1776: Improving Access to Affordable Prescription Drugs Act S. 808: Sports Medicine Licensure Clarity Act S. 989/ H.R. 3767: Ensuring Childrens Access to Specialty Care Act S. 1131/ H.R. 2439: FAIR Drug Pricing Act S. 1827/ H.R. 3921 HEALTHY KIDS Act S. 2260 / H.R. 4733: Opioids and STOP Pain Initiative Act H.R. 3197: PUPPERS Act H.R. 3928: Truth in Healthcare Marketing Act of 2017 H.R. 4116: Transparent Drug Pricing Act of 2017 Reauthorization of the Pediatric Subspecialty Loan Repayment Program in Title VII; Maintenance/expansion of Graduate Medical Education (GME); CDC funding; NIH funding including the BRAIN Initiative; DACA renewal; Congressionally-Directed Medical Research Program funding; concussion related issues.
Client expense: Not reported · Firm income: $170,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · fourth_quarter · Pharmacy
S 771/HR1776-Improving access to affordable prescription drugs act, S 2011/HR 4138-Medicare Price Negotiation Act of 2017, S 252-Medicare Drug Savings Act of 2017, S 1369/HR 2974-Stop Price Gouging Act, S 124-Preserve access to affordable generics act, HR 4117-Competitive DRUGS Act of 2017, S 974/HR 2212-CREATES act of 2017, HR 2051-FAST generics Act of 2017, S 495-Medicare Innovation Prize Fund Act, S 1131.HR 2439-FAIR Drug Pricing act, HR 4116-Transparent Drug Pricing Act of 2017, S 1509-Orphan Products extension accelerating cures and treatments, HR 1223-OPEN act, S 1390-Stronger Patriots Act of 2017, S 1827-KIDS Act of 2017, HR 1628-American Health care act of 2017, HR 3921-Healthy KIDS Act, HR 4116-Transparent drug pricing act of 2017, Bipartisan Health Care Stabilization Act of 2017, biologic market exclusivity, inter partes review, direct to consumer advertising, Over-the-counter Monograph Safety Innovation and Reform act of 2017, Azar HHS nomination,
Client expense: $70,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Education, Dept of, Federal Communications Commission (FCC), HOUSE OF REPRESENTATIVES, Office of Government Ethics (OGE), SENATE, Securities & Exchange Commission (SEC), U.S. Trade Representative (USTR), White House Office
2017 · fourth_quarter · Health Issues
S. 1976 - Increasing Access to Care Act H.R. 4200 - Healthcare Market Certainty and Mandate Relief Act of 2017 H.R. 3928 - Truth in Healthcare Marketing Act of 2017 S. 2001 - State Public Option Act H.R. 4129 - State Public Option Act H.R. 4128 - Health Care Choice and Affordability Act H.R. 4695 - Bipartisan Market Stabilization and Innovation Act of 2017 S. 2256 - Tax Extender Act of 2017 S. 2253 - CHIP Mental Health Parity Act H.R. 4666 - Premium Relief Act of 2017 H.R. 4620 - Protecting Families and Small Businesses Act of 2017 H.R. 4613 - Ensuring Patient Access to Healthcare Records Act of 2017 H.R. 4575 - Access to Independent Health Insurance Advisors Act of 2017 H.R. 4579 - Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017 S. 2021 - Health Care Choice Act of 2017 H.R. 3921 - HEALTHY KIDS Act S. 1970 - Medicare-X Choice Act of 2017 H.R. 4094 - Medicare-X Choice Act of 2017 H.R. 4733 - Opioids and STOP Pain Initiative Act S. 2260 - Opioids and STOP Pain Initiative Act S. 2183 - CHIP Stability Act H.R. 4541 - CHAMPION KIDS Act of 2017 H.R. 4613 - Ensuring Patient Access to Healthcare Records Act of 2017 H.R. 4482 - Opioid Abuse Deterrence, Research and Recovery Act of 2017 H.R. 4515 - To amend title XXI of the Social Security Act to provide for a special rule during the first quarter of fiscal year 2018 for the redistribution of certain Childrens Health Insurance Program allocations for certain shortfall States. S. 2172 - Medical Innovation Act of 2017 H.R. 4456 - Health Care Sharing Fairness Act S. 2157 - Drug-Price Transparency in Communications Act H.R. 4408 - Opioid Addiction Prevention Act of 2017 H.R. 4404 - State CHIP Flexibility Act of 2017 S. 2132 - Family Coverage Act H.R. 4394 - Bare County Buy-in Act of 2017 S. 2121 - Ensuring Access to Air Ambulance Services Act of 2017 H.R. 4206 - Medicare Care Coordination Improvement Act of 2017 S. 2052 - Health Care Market Certainty and Mandate Relief Act S. 2051 - Medicare Care Coordination Improvement Act of 2017 S. 2050 - Health Care Market Certainty and Mandate Relief Act H.R. 4116 - Transparent Drug Pricing Act of 2017 S. 1978 - Small Business and Family Health Tax Relief Act of 2017 H.R. 4004 - To amend the Patient Protection and Affordable Care Act to require employees of the White House to enroll in Obamacare, and for other purposes. H.R. 3976 - Access to Marketplace Insurance Act H.R. 3964 - Opioid Addiction Prevention Act of 2017 H.R. 3927 - To amend title XXI to allow for the blending of risk pools of childrens health insurance buy-in programs with the risk pools of State child health plans under such title, and for other purposes H.R. 3919 - Commonsense Reporting Act of 2017 S. 1909 - BENES Act of 2017 S. 1908 - Commonsense Reporting Act of 2017 H.R. 1319 - Local and Municipal Health Care Choice Act of 2017 H.R. 3798- Save American Workers Act of 2017
2017 · fourth_quarter · Advertising
H.R. 1, An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018 H.R.1776/ S.771, Improving Access To Affordable Prescription Drugs Act H.R. 2439/ S.1131, Fair Accountability and Innovative Research Drug Pricing Act S.1348, Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act H.R.4385, Responsibility in Drug Advertising Act H.R.4116, Transparent Drug Pricing Act S.2157, Drug-Price Transparency in Communications Act FTC Reauthorization Act of 2017 (Not introduced)
Client expense: Not reported · Firm income: $110,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · fourth_quarter · Medicare/Medicaid
General Medicare Protection, Prevention of Fraud, Waste, and Abuse, Prescription Drug Re-Importation: S. 92 and S. 469 and H.R. 1245, Negotiation of Prescription Drug Prices: H.R. 242 and S. 41, General Prescription Drug Affordability: S. 124 and S. 771 and H.R. 1776 and H.R. 4138 and H.R. 4116 and H.R. 4117 and S. 2011, Medicare Enrollment Simplification: H.R. 2575 and S. 1909.
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
| Democratic |
| NH |
| Chellie Pingree | Democratic | ME |
| David N. Cicilline | Democratic | RI |
| Earl Blumenauer | Democratic | OR |
| Eleanor Holmes Norton | Democratic | DC |
| Elijah E. Cummings | Democratic | MD |
| Emanuel Cleaver | Democratic | MO |
| Grace F. Napolitano | Democratic | CA |
| Gwen Moore | Democratic | WI |
| Henry C. "Hank" Johnson, Jr. | Democratic | GA |
| Jamie Raskin | Democratic | MD |
| Jerrold Nadler | Democratic | NY |
| John Conyers, Jr. | Democratic | MI |
| Judy Chu | Democratic | CA |
| Karen Bass | Democratic | CA |
| Keith Ellison | Democratic | MN |
| Luis V. Gutiérrez | Democratic | IL |
| Marcy Kaptur | Democratic | OH |
| Mark DeSaulnier | Democratic | CA |
| Mark Pocan | Democratic | WI |
| Mark Takano | Democratic | CA |
| Maxine Waters | Democratic | CA |
| Nydia M. Velázquez | Democratic | NY |
| Peter Welch | Democratic | VT |
| Pramila Jayapal | Democratic | WA |
| Raúl M. Grijalva | Democratic | AZ |
| Ro Khanna | Democratic | CA |
| Rosa L. DeLauro | Democratic | CT |
| Steve Cohen | Democratic | TN |
| Vicente Gonzalez | Democratic | TX |
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Client expense: $330,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Labor, Dept of (DOL), SENATE, Treasury, Dept of, White House Office